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 CASE REPORT
The authors report the case of a 62 -year -old Cau-
casian male with a personal history of hypertension, 
diabetes, and chronic kidney disease of unknown 
aetiology, who began haemodialysis in February 
2009.
He was submitted to renal transplantation of a 
60 -year -old deceased donor (death from cerebrovas-
cular accident) on September 29, 2014. Both the donor 
and the recipient had the same ABO and Rhesus blood 
type (O+). The recipient had 2 HLA -mismatches (1 in 
AB and 1 in DR), a panel reactive antibody (PRA) of 0%, 
negative CDC crossmatch for B and T lymphocytes and 
anti -HLA alloantibody class I and II research using 
Luminex® technology was negative.
The immunosuppression protocol was basiliximab 
(first and fourth post -transplant days), methylpredni-
solone (500 -250 -125 -80mg on 1 -4 post -transplant days, 
respectively), prednisolone (35 mg at 5 post -transplant 
day, followed by progressive tapering until nearly 5mg 
at 30 post -transplant day), cyclosporine (175 mg twice 
daily with target levels achieved) and mycophenolate 
mofetil (1000mg twice daily).
After the surgery the patient presented delayed graft 
function (DGF). The patient needed one dialysis session 
due to hyperkalaemia. At discharge date, eleven days 
 ABSTRACT
Over the last 15 years, better immunosuppressive drugs have decreased acute rejection rates in kidney trans-
plantation but have also led to an increase in the incidence and impact of BK virus nephropathy. The authors 
report the case of a 62 -year -old man submitted to a renal transplant of a deceased donor with an immunosup-
pression regimen free of rabbit anti -thymocyte globulin and tacrolimus, in whom BK nephropathy was diagnosed 
at seven weeks post -transplant. Intravenous human immunoglobulin (IVIG) was administered after immunosup-
pression reduction. Instituted treatment was successful. This clinical case highlights the importance of a high 
index of suspicion for an atypical presentation of BK nephropathy in renal transplant recipients and strengthens 
the need for other therapeutic interventions beyond the reduction of immunosuppression. It was the starting 
point for a review of BK virus nephropathy in kidney transplantation with a focus on risk factors, diagnosis and 
treatment.
Key -Words: Atypical presentation, BK virus, early diagnosis, kidney transplant, nephritis, therapeutic interventions.
260    Port J Nephrol Hypert 2016; 30(4): 259-268
post -transplant, his serum creatinine (SCr) was 2.53 
mg/dL. Progressive reduction of immunosuppression 
was made because of pancytopaenia, and even pred-
nisolone was quickly tapered to the maintenance dose 
due to uncontrolled glycaemia.
Eighteen days post -transplant he presented BK virus 
positivity in urine (identification of decoy cells on analy-
sis of urine cytology). The patient presented progressive 
improvement of graft function and two weeks later 
had a SCr of 1.02 mg/dL.
He was admitted seven weeks post -transplant for 
acute graft dysfunction (with SCr 2.56 mg/dL). On that 
date his maintenance immunosuppression was cyclo-
sporine 150mg twice daily, mycophenolate mofetil 
250mg twice daily and prednisolone 7.5mg daily. A 
positive BK viraemia of 197250 copies/mL was detected 
[by quantitative polymerase chain reaction (PCR) in 
plasma]. Immunosuppression was immediately reduced 
(cyclosporine was reduced to 100 mg twice daily and 
mycophenolate mofetil was suspended) and a cipro-
floxacin course was initiated (250mg 12/12h). Obstruc-
tion was excluded and the patient was hydrated. Graft 
pyelonephritis by Enterococos faecalis was diagnosed. 
He was treated with amoxicillin -clavulanic acid and the 
pigtail was removed. He had partial graft function recov-
ery (SCr 1.9 mg/dL). Graft biopsy was performed one 
week after admission, which was compatible with poly-
omavirus associated interstitial nephritis (BK virus 
nephropathy). Non -specific intravenous human immu-
noglobulin 1 g/Kg was administered in 2 divided doses 
one month apart. One month and two weeks after the 
mentioned treatment, graft function improved (SCr 
1.5mg/dL) and viraemia disappeared.
 REVIEW
Over the last 15 years, more potent immunosup-
pression regimens have decreased the rates of acute 
rejection in kidney transplantation but simultaneously 
have led to the emergence of BK virus nephropathy1.
BK is a DNA virus from the polyomavirus family, 
which includes JC virus. Based on DNA sequence vari-
ations, BK can be divided into six genotypes. Genotype 
I is the most frequent worldwide (80%), followed by 
genotype IV (15%)2. The BK genome encodes three 
capsid structural proteins, called viral capsid protein 1 
(VP1), VP2 and VP3, as well as the large T and small t 
antigens.
Primary infection is often subclinical or manifests as 
mild respiratory illness and is acquired in childhood; BK 
virus is almost ubiquitous in adults with seroprevalence 
of 80%3. After primary infection, the virus establishes 
latency in the uroepithelium renal and particularly in 
tubular epithelial cells. In the setting of immunosup-
pression, the virus reactivates and begins to replicate, 
triggering a cascade of events starting with tubular cell 
lysis and consequent viruria. The BK virus then multiplies 
in the interstitium and crosses into the peritubular capil-
laries, causing viraemia and may also invade the allograft 
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Figure 1
Nuclear enlargement in tubular epithelium (H&E; x200)
 
Figure 2
Intranuclear inclusions in tubular epithelium (H&E; x400)
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interstitium, leading to the tubulointerstitial lesions that 
characterize BK virus nephropathy4.
Approximately 20 to 60% of renal transplant recipi-
ents present viruria; one third of patients with viruria 
will develop BK viraemia and BK virus nephropathy 
develops in 2 to 10% of recipients5.
The most consistent risk factor identified across stud-
ies for the development of BK virus nephropathy is the 
overall level of immunosuppression6. Other risk factors 
identified for BK virus nephropathy which have not 
been uniformly observed in all studies include male 
gender, older and younger age, white ethnicity, diabetes 
mellitus, DGF, rejection episodes, degree of human 
leukocyte antigen (HLA) mismatching, prolonged cold 
ischaemia, BK serostatus, ureteral trauma/ureteral 
stent placement, cytomegalovirus infection and gluco-
corticoid maintenance therapy5 -12.
Induction and also maintenance immunosuppression 
seems to influence BK virus nephropathy risk. 
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Figure 3
Intranuclear inclusions in tubular epithelium (H&E; x400)
 
Figure 5
Interstitial mononuclear inflammation (H&E; x100)
 
Figure 4
Interstitial mononuclear inflammation (H&E; x100)
 
Figure 6
Positive SV40 staining (SV40; x100)
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Dharnidharka et al demonstrated that the use of rabbit 
anti -thymocyte globulin induction and tacrolimus or 
mycophenolate mofetil based immunosuppression 
increased the risk for the development of BK viraemia13. 
Hirsch et al performed a secondary analysis of the data 
of the DIRECT trial which was a prospective, randomized 
trial of cyclosporine versus tacrolimus in conjunction 
with basiliximab induction14. They showed that patients 
in the cyclosporine arm had a lower rate of BK virus 
nephropathy at 6 and 12 months post -transplant, com-
pared with the tacrolimus group. This result supports 
an effect of more potent maintenance immunosuppres-
sion on BK reactivation. It has been shown that the risk 
of BK virus nephropathy is higher in recipients that 
received maintenance immunosuppression with 
tacrolimus -mycophenolate mofetil, or prednisone ver-
sus no prednisone, tacrolimus versus cyclosporine, high 
versus low levels of tacrolimus, and high versus low 
doses of prednisone15. Prospective studies designed to 
address the effect of induction and maintenance immu-
nosuppression on BK virus nephropathy are needed4.
Rejection and/or ischaemia of the kidney allograft 
may increase the risk of BK nephropathy16. This state-
ment is based on the fact that BK virus nephropathy 
rarely occurs in the native kidneys of patients who 
undergo non -renal solid organ transplantation, despite 
immunosuppression17,18.
BK virus nephropathy may be higher among human 
leukocyte antigen (HLA) - and ABO -mismatched patients, 
which may be due to the increased rate of rejection 
and increased immunosuppression among such 
patients19. The risk among ABO -incompatible patients 
seems to be higher than among HLA -mismatched 
patients. ABO incompatibility was inclusively assumed 
as an independent predictor of BK virus nephropathy 
in the study of Sharif A et al11.
Currently, pre -transplant screening of donors and 
recipients for BK seropositivity is neither mandatory 
nor routinely performed. Nevertheless, although pre-
-transplant BK seropositivity in adult recipients has not 
been shown to influence the development of BK virus 
nephropathy after transplantation20,21, Bohl et al iden-
tified BK virus antibody -positive donors as a risk for 
post -transplant BK viraemia in recipients20. In this study, 
recipients of BK seropositive donor kidneys developed 
BK viraemia at earlier post -transplant timepoints; had 
higher viral titers and were slower to clear the virus. 
This data suggests a role for donor pre -transplant sero-
typing as a means of BK risk assessment and immuno-
suppression management.
The induction of immunosuppression in our patient 
was not based on rabbit anti -thymocyte globulin but 
on basiliximab; and in spite of tacrolimus he had cyclo-
sporine as maintenance immunosuppression. Accord-
ing to collected data concerning induction and main-
tenance immunosuppression regimens, this patient did 
not belong to a recipients’ group at a higher risk of 
developing BK virus nephropathy. However, he pre-
sented several risk factors that contributed to the 
increase in his overall degree of immunosuppression: 
history of diabetes mellitus and the development of 
pancytopaenia. In addition, other risk factors not uni-
versally accepted were also present, such as male gen-
der, older age, white ethnicity and DGF. Therefore the 
diagnosis hypothesis of BK virus nephropathy would 
be more plausible than it first seemed.
Among kidney transplant recipients, BK virus causes 
tubulointerstitial nephritis and seldom ureteral steno-
sis22. Haemorrhagic and non -haemorrhagic cystitis is 
rarely observed among this subgroup of patients, 
although it may be a complication in bone marrow 
transplantation23,24.
Patients with BK virus nephropathy most commonly 
present with an asymptomatic acute or slowly progres-
sive rise in serum creatinine concentration25. Routine 
urinalysis most commonly reveals pyuria, haematuria 
and/or cellular casts consisting of renal tubular cells 
and inflammatory cells, which are suggestive findings 
of interstitial nephritis.
Prospective screening studies have demonstrated 
that BK virus nephropathy is predominantly an early 
complication of renal transplantation, with most cases 
occurring within the first year post -transplantion4, with 
disease onset occurring at mean 10 to 13 months post-
-transplantation. However, the onset of nephritis may 
occur as early as six days post -transplantation, or as 
late as five years23,26–,28.
Literature supports that such an early BK virus 
nephropathy presentation, as occurred with our 
patient, is rare but it has already been described. We 
emphasize that, in our case, BK virus nephropathy pre-
sented nearly seven weeks post -transplant, much ear-
lier than three months which is when several centers 
begin screening for BK virus infection.
BK virus nephropathy is first suspected in the patient 
with clinical findings suggestive of interstitial nephri-
tis19. The suspicion of the diagnosis is supported by 
the identification of decoy cells on analysis of urine 
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cytology and/or by quantitative polymerase chain reac-
tion (PCR) of urine and/or plasma19. A definitive diag-
nosis of BK virus nephropathy is made by analysis of 
tissue obtained by renal biopsy19. However the diag-
nosis may be missed on biopsy since definitive lesions 
have a focal distribution. As BK virus nephropathy has 
limited treatment options, the goal of screening is to 
facilitate early diagnosis of patients when viruric or 
viraemic, and to intervene prior to the development 
of overt nephropathy4.
BK viral infections progress through recognized 
stages. Viral replication in the urine precedes BK virae-
mia by nearly four weeks and BK virus nephropathy 
occurs nearly 12 weeks after BK viruria5. Renal trans-
plant recipients with higher urine DNA levels are more 
likely to develop detectable DNA in plasma, and pro-
longed DNAemia usually precedes clinically overt 
nepropathy19.
The approach to the evaluation of patients with sus-
pected BK nephritis varies by institution and their sur-
veillance protocols. One possible approach is first to 
screen by using urine cytology and, if positive on two 
successive occasions over four weeks and plasma PCR 
is positive (DNA PCR load > 104 copies/ml), an allograft 
biopsy is obtained regardless of renal function4,19. 
Based on the available literature4, one responsible 
approach is to routinely screen all renal transplant 
patients starting at 3 months until 24 months post-
-transplantation. Screening is not recommended out 
of that period once BK virus nephropathy is rare, unless 
renal dysfunction is present.
BK virus is detectable in both blood and urine4. BK 
viral loads are measured by PCR. Viruria is defined as 
presence of >2000 copies/mL of urine and viraemia is 
defined as presence of >2000 copies/mL of whole 
blood. The sensitivity and specificity of the PCR appears 
to be institution dependent and must be interpreted 
according to clinical setting19.
Urine can be screened for BK virus by cytology or 
by quantification of urine BK DNA by PCR4. Tubular 
epithelial cells infected with BK virus are shed in the 
urine and are called “decoy cells”4 (due to their resem-
blance to renal carcinoma cells). Cytological examina-
tion of urine may reveal such BK -infected cells. Their 
most characteristic abnormality is an enlarged nucleus 
with a single large basophilic intranuclear inclusion. 
The presence of characteristic cytopathology changes 
in infected cells is strongly suggestive of BK virus infec-
tion19. Thus, urine cytology showing characteristic 
cytological abnormalities is suggestive, but not defini-
tive, for BK virus nephropathy. Their absence does not 
exclude the disease. Urine BK PCR is more sensitive 
and specific than urine cytology for the detection and 
diagnosis of BK virus nephropathy29 (100% sensitivity 
and 78% specificity for urine PCR vs 25% and 85%, 
respectively, for the presence of decoy cells in urine 
cytology). If only urine BK virus screening is to be per-
formed, urine BK PCR is recommended as the superior 
assay, considering the threshold of >1x107 copies/mL 
as suggestive of BK virus nephropathy4. Given the wide-
spread availability of the plasma PCR assay and its 
greater predictive value for BK virus nephropathy, it 
may be unnecessary to perform urine BK screening first 
before plasma testing4.
BK detection by PCR in plasma is very sensitive and 
specific for the development of BK virus nephropathy. 
Depending on the study, sensitivity can achieve 100% 
and specificity is almost 90%20,29. A definitive viral load 
cut -off associated with BK virus nephropathy has not been 
established yet, but retrospective studies have suggested 
that a BK viral load >104 copies/mL is strongly associated 
with the presence of BK virus nephropathy5.
The patient previously reported presented decoy 
cells on urine cytology eighteen days post -transplant. 
It is important to mention that, in this case, urine cytol-
ogy was requested sooner than usual because this 
patient had an elevated creatinine level (SCr 2.53mg/
dL) at discharge. Even though he had achieved a normal 
graft function (Scr 1.02mg/dL) transiently, seven weeks 
post -transplant he presented acute graft dysfunction 
associated to a much higher BK viraemia than the 
threshold above which renal biopsy is mandatory. This 
case is in accordance with the progression of BK virus 
infections through detectable stages advocated by lit-
erature (Table I). This patient probably, developed BK 
virus infection in the first fewdays post -transplant.
Renal biopsy remains the gold standard for the diag-
nosis of BK virus nephropathy. It is recommended in 
patients with a high level of BK viraemia (>104 copies/
mL) with or without an elevation in serum creatinine4.
A definitive diagnosis of BK virus induced nephropa-
thy requires the following findings on renal biopsy: 
characteristic cytopathic changes plus positive immu-
nohistochemistry tests using antibodies directed spe-
cifically against BK or against the cross -reacting SV40 
large T antigen. Positive SV40 staining is pathogno-
monic as it is associated with a specificity of almost 
100 percent19.
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The characteristic cytopathic changes mentioned 
above include: intranuclear basophilic viral inclusions 
without a surrounding halo; interstitial mononuclear 
or polymorphonuclear cell infiltrates in the areas of 
tubular damage; tubular injury which is characterized 
by tubular cell apoptosis, cell drop out, desquamation, 
and flattened epithelial lining, and tubulitis which is 
manifested by lymphocyte permeation of the tubular 
basement membrane that can be mistaken for acute 
cellular rejection23,26,30,31.
Three patterns have been proposed to describe the 
histological findings in patients with BK virus nephropa-
thy19: pattern A consists of cytopathic/cytolytic changes 
with absent or minimal inflammation; pattern B consists 
of cytopathic/cytolytic changes associated with patchy 
or diffuse tubulointerstitial inflammation and atrophy, 
and pattern C consists of graft sclerosis. Therefore the 
degree of fibrosis and tubular atrophy are assumed to 
be the most predictive of allograft outcome4.
Because of the focal nature of early BK nephropathy, 
the diagnosis may be missed in one -third of biop-
sies32,33, making diagnosis on occasion challenging. 
Owing to these difficulties, a negative biopsy cannot 
rule out early BKVN with 100% certainty. A minimum 
of two biopsy cores, preferably including medulla, 
should be examined34. Medullary tissue should be 
included because the virus is more likely to be present 
in the medulla. If the initial biopsy does not confirm 
BK, a biopsy repetition should be considered.
A presumptive diagnosis of BK virus nephropathy 
may be made in the absence of definitive findings on 
biopsy. Findings of sustained (more than two weeks of 
duration) urinary viral shedding and significant BK rep-
lication (plasma DNA PCR load > 104 copies/mL) with 
or without kidney dysfunction defines presumptive BK 
nephropathy5,32.
Our patient´s renal biopsy showed the characteristic 
cytopathic changes of BK virus nephropathy, namely 
the intranuclear basophilic viral inclusions in tubular 
cells and interstitial mononuclear cell infiltrate accom-
panied by positive SV40 staining. It allowed the defini-
tive diagnosis of BK virus nephropathy. This result was 
unexpected in view of the timing of the development 
and the immunosuppressive regimen used. Thus, the 
other possible diagnosis hypothesis of cellular acute 
rejection became less probable, although the coexist-
ence of both entities at the date the renal biopsy was 
performed could not be completely excluded. As cel-
lular acute rejection shares similar features, such as 
interstitial mononuclear cell infiltrate and tubulitis, with 
BK virus nephropathy the distinction between them is 
not always easy but is crucial as the treatment of rejec-
tion is the opposite of that required for BK virus 
nephropathy. In view of the patient´s clinical response 
to immunosuppression reduction, the possibility of 
rejection was afterward definitely excluded.
Cellular adaptative immunity is determinant for the 
control and resolution of BK virus nephropathy. CD4+ 
and CD8+ cells are implicated in BK clearance. In kidney 
transplant recipients, a strong CD8 response was associ-
ated with lower BK viral loads in blood and urine4,15.
There is no objective data concerning BK virus 
nephropathy treatment, as current therapeutic recom-
mendations are largely based on small case 
series5,23,25,35. This is a worrisome problem since estab-
lished BK virus nephropathy is associated with allograft 
failure in 15 to 50 percent of cases.
Evidence suggests that prevention consisting of a 
screening and pre -emptive approach is more effective 
than a strategy based on therapy of established dis-
ease35.  Several studies have evaluated the efficacy of 
screening with subsequent immunosuppression reduc-
tion20,34,36,37. They concluded that BK viruria without 
viraemia poses minimal risk; that the minimization of 
immunosuppression upon detection of BK viraemia is 
associated with excellent graft survival, low rejection 
rates and preserved renal function at five years, and 
that such an approach may prevent clinically evident 
BK virus nephropathy. These outcomes have been 
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Table I
Stages of BK viral infection, its timing of emergence and affected transplant recipients rate
BK viral infection stages Timing of emergence Affected transplant recipients rate
Viruria 3 months to 2 years posttransplant
(mean: 10 to 13 months posttransplant)
20 -60%
Viraemia 4 weeks after viruria development 10 -30%
BK virus nephropathy 12 weeks after viraemia development 2 -10%  
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strengthened by more recent studies38 -40. Sawinski et 
al4 recommend that patients who have their immuno-
suppression reduced for BK viraemia should be moni-
tored carefully, with serum creatinine checked every 
1 -2 weeks and BK viral loads repeated at 2 -4 week 
intervals. Few observational studies have reported suc-
cessful clearance of viraemia of > 85 percent with 
immunosuppression reduction15.
When BK virus nephropathy is established, immu-
nosuppression reduction remains the cornerstone of 
therapy25,41. However, in this stage, treatment becomes 
more complex and immunosuppression reduction alone 
is often not sufficient to stabilize renal function. The 
main objective of immunosuppression reduction is to 
restrain viral replication without triggering rejection, 
but the optimal method to achieve it is unclear. The 
particular regimen is frequently center specific42. One 
approach that is used for patients who are on a main-
tenance regimen consisting of triple immunosuppres-
sion therapy with a calcineurin inhibitor (cyclosporine 
or tacrolimus), an antimetabolite (azathioprine, 
mycophenolate mofetil) and prednisone is to discon-
tinue completely the anti -metabolite (usually mycophe-
nolate) and decrease the dose of the calcineurin inhibi-
tor. Additional interventions are based upon the clinical 
response to this initial strategy as measured by the 
reduction in BK viraemia load after a period of one to 
two months. The resolution of viraemia may take sev-
eral months. An alternative approach that is used by 
others is to decrease the mycophenolate dose by 50 
percent, followed by a 50 percent decrease in the cal-
cineurin inhibitor at three months if decoy cells persist. 
Using this approach, the target serum tacrolimus trough 
level is 4 to 6 ng/mL, and the target serum cyclosporine 
trough level is 60 to 100 ng/mL. Mycophenolate may 
be discontinued completely if viral activation persists. 
Maintenance immunosuppression then consists of tac-
rolimus and low -dose prednisone.
Discontinuation of the anti -metabolite is the most 
common approach and a recent study43 suggested that 
both tacrolimus and cyclosporine can inhibit anti -BK 
T -cell responses in vitro, strengthening this practice4.
For patients who have progressive allograft dysfunc-
tion, despite a maximal decrease in immunosuppressive 
therapy for a period of several weeks to months, agents 
with hypothetical antiviral activity may be tried. How-
ever the efficacy of this approach has not been prov-
en44. Antiviral agents that have been associated with 
anecdotal success include intravenous immune globulin 
(IVIG) and cidofovir42. Regardless of the treatment 
strategy employed, rapid viral reduction has been asso-
ciated with stable or improving glomerular filtration 
rate (GFR)4. Treatment is based on biopsy findings: if 
the kidney biopsy is compatible with BK virus nephropa-
thy and simultaneously has an important interstitial 
inflammation, treatment options include administra-
tion of IVIG, immunosuppression reduction and anti-
viral therapy; if the kidney shows findings of BK virus 
nephropathy but without significant interstitial inflam-
mation, treatment shall include immunosuppression 
reduction and antiviral therapy; and if the biopsy does 
not show evidence of BK nephropathy, immunosup-
pression reduction and continued blood BK viral load 
monitoring every two weeks until the assay becomes 
negative is recommended.
The reported efficacy of adjuvant antiviral agents is 
difficult to interpret because they have been used in 
combination with immunosuppression reduction and, 
occasionally, in combination 42. So there are no rand-
omized controlled trials showing superiority of these 
drugs over the timely reduction of immunosuppression; 
additionally, the United States Food and Drug Admin-
istration has not approved any specific drug for the 
treatment of BKV15.
We will specifically focus on intravenous human 
immunoglobulin, cidofovir, leflunomide, fluoroquinolo-
nes and mTOR inhibitors.
Intravenous human immunoglobulin (IVIG) therapy 
has immunomodulatory effects on inflammation and 
autoimmune diseases through formation of immuno-
globulin complexes and it has also shown potential 
anti -BK virus properties45. It has been administered in 
doses of 0.2 -2.0g/Kg together with reduction of the 
immunosuppression42. A recent study46 assessed the 
impact of treatment with IVIG in 30 renal transplant 
recipients with BK virus nephropathy previously submit-
ted to 8 weeks immunosuppression reduction and 
leflunomide without response. Ninety percent of 
patients presented a positive response in clearing virae-
mia. It was concluded that IVIG administration appeared 
to be safe and effective in treating BK virus nephropathy 
and preventing graft loss in patients who had inade-
quate response to immunosuppression reduction and 
leflunomide therapy. The authors argued that the 
administration of IVIG for treating BK virus nephropathy 
not only reduces the BK viral load but also seems to 
offer additional protection against acute rejection dur-
ing the reduction of immunosuppression. This study 
had the largest sample size using IVIG treatment in 
patients with persistent BK virus nephropathy.
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Cidofovir is a cytosine nucleotide analogue that is 
active against various DNA viruses and is approved for 
both human immunodeficiency virus (HIV) associated 
cytomegalovirus retinitis and the topical treatment of 
genital warts42. Its mechanism of action in BK virus 
infection is not yet clear. It has in vitro activity against 
BK virus, but the results of in vivo activity are contradic-
tory15. However, cidofovir is highly nephrotoxic, result-
ing in proteinuria and renal failure in 20 percent of 
patients42. To treat BK nephropathy, cidofovir is admin-
istered at low doses of 0.25 -1mg/Kg every 1 to 3 
weeks15. Monitoring should include creatinine, leuko-
cyte count, visual symptoms, and plasma viral load 
every 2 weeks. Among the most important adverse 
effects reported is anterior uveitis in up to 12 to 35 
percent of cases. Some studies report stabilization of 
renal function47,48, whereas others report no demon-
strable benefit49,50.
Brincidofovir (CMX001), administrated orally, is a 
lipid conjugate of the acyclic nucleotide phosphonate 
cidofovir. Unlike cidofovir, CMX001 is not concentrated 
in the proximal tubules of the kidney and is unlikely to 
produce renal toxicity51. It has been proven effective 
against polyomavirus52.
Leflunomide is a prodrug whose active metabolite 
A771726 (teriflunomide) has both immunosuppressive 
and antiviral activity53. Although currently approved 
for treatment of rheumatoid arthritis, several reports 
describe its use in treatment of BK virus nephropathy54 -56. 
Despite there being limited experience with this drug, 
leflunomide in combination with a low -dose calcineurin 
inhibitor and prednisone seems to facilitate virus clear-
ance and to stabilize graft function without increasing 
the risk of graft rejection53. Leflunomide has a modest 
activity in vitro by blocking replication of BKV, but its 
mechanism of action against BK virus is unknown15. It 
is also active in vivo against other DNA viruses, such as 
CMV and herpes simplex virus. It is administered orally, 
with a loading dose of 100mg/day during 5 days fol-
lowed by a maintenance dose of 40mg/day. Patients 
undergoing this treatment must have blood counts and 
liver function once a month and BKV loads every 2 
weeks. Reported side effects with leflunomide are 
hepatitis, haemolysis, thrombotic microangiopathy, 
aplastic anaemia, and fungal pneumonia. In some but 
not all studies therapeutic response is associated with 
levels of between 40 and 100 ug/mL57 -59. However, 
the wide interpatient level variability, the limited avail-
ability of A771726 levels assays and the potential for 
haematologic and hepatic toxicity preclude routine use 
of leflunomide for BK virus infections42.
FK778 is a derivative of the active metabolite of 
leflunomide and inhibits pyrimidine biosynthesis to 
prevent lymphocyte proliferation. One study60 has 
assessed the efficacy of FK778 for the treatment of BK 
virus nephropathy. FK778 did decrease BK viraemia and 
BK viruria in patients treated with it, but acute rejection 
rates and incidence of allograft loss in the FK778 treat-
ment group were much higher than in the immunosup-
pression reduction group. No further studies using 
FK778 are planned.
A recent systematic review61 suggested that the 
addition of leflunomide or cidofovir to immunosup-
pression reduction does not result in a decrease in the 
rate of allograft failure. However, the evidence base is 
poor and highlights the urgent need for randomized 
trials to define the adequate adjunctive therapy for 
cases of BK virus nephropathy with no response to 
immunosuppression reduction alone.
Fluoroquinolones have shown in vitro activity against 
BKV42. They inhibit bacterial replication by inhibiting 
type II topoisomerases and have activity against BKV 
helicase, which is encoded by the long T antigen, 
although with low selectivity index62,63. However, two 
recent randomized trials64,65 showed no benefit of 
levofloxacin given either prophylactically immediately 
following transplantation, or as treatment for active 
BK viraemia.
Sirolimus and the newer mTOR inhibitor, everolimus, 
reduce BKV large T antigen expression in vitro66. There-
fore, the potential effect of mTOR inhibitors may be 
not only from lowering the intensity of immunosup-
pression but also by a more direct effect. A mTOR inhibi-
tor based regimen is associated with lower rates of 
BKV infection in clinical studies. Furthermore it has the 
advantages of a lower viraemia peak and a faster reso-
lution of BK viraemia when infection occurs66. Its use 
in this setting deserves further investigation. A recently 
published study67 concluded that everolimus conver-
sion for the treatment of BKV infection is promising 
but did not reach statistical significance. Currently a 
randomized trial comparing the efficacy of reduction 
of immunosuppression versus substitution of tacroli-
mus for sirolimus to the treatment of BK viraemia or 
BK virus nephropathy is ongoing.
Prospective randomized studies with a longer follow-
-up are still needed to evaluate different treatment 
strategies while assessing the possibility of chronic 
allograft dysfunction due to systematic reduction of 
immunosuppression.
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In what concerns our patient´s treatment, despite 
being submitted to progressive immunosuppression 
reduction since the first days post.transplant, he devel-
oped BKV nephropathy one month and three weeks 
post -transplant. In this setting we decided to associate 
IVIG as an antiviral agent at diagnosis date. Beyond 
current available literature that reports anecdotal suc-
cess with IVIG, the finding of an important interstitial 
inflammation in his renal biopsy contributed to our 
option. Six weeks after treatment with IVIG our patient’s 
viraemia had resolved and graft function improved (SCr 
1.9  -> 1,5mg/dL). Our favorable outcome with IVIG is 
supported by the recent study of Vu D et al52 which 
concluded that IVIG is effective in treatment of BK virus 
nephropathy in recipients unresponsive to the combi-
nation therapy of immunosuppression reduction and 
leflunomide therapy. Even though we did not wait 8 
weeks for the absence of response after maximal immu-
nosuppressive reduction nor used leflunomide, we 
observed a significant decrease of BK viral load within 
1 month of IVIG treatment, accompanied by improve-
ment of graft function, as reported in this study. 
Although IVIG therapy is expensive, this cost may be 
justified in selected patients in light of the fact that BK 
virus nephropathy may compromise graft survival.
Retransplantation after allograft loss due to BK virus 
nephropathy is a reasonable option, although it has 
been recommended that the absence of BK replication 
should be confirmed prior to retransplantation5. 
Because BK nephropathy appears to be donor derived 
and cytotoxicity mediated, this usually necessitates 
intense screening for the activation of BK virus in the 
new allograft42. Transplant nephrectomy in patients 
with failed graft due to BK virus nephropathy has not 
been found protective after retransplantation4.
 CONCLUSION
This case illustrates the importance of a high index 
of suspicion to an atypical presentation of BK virus 
nephropathy in renal transplant recipients, since this 
entity is currently a real threat to allograft survival. In 
spite of an early presentation (before 3 months post-
-transplantation) and the absence of immunosuppres-
sion regimen based on rabbit anti -thymocyte globulin 
and tacrolimus (typically associated with BK virus 
nephropathy), this patient presented several risk factors 
that contributed to increasing his overall degree of 
immunosuppression, including history of diabetes mel-
litus and the development of pancytopaenia. Therefore 
the diagnosis hypothesis of BK virus nephropathy was 
more plausible than it first seemed.
A tight screening is determinant in order to detect 
the early stages of BK virus infection (when patients 
are still viruric or viraemic) and to intervene prior to 
the development of overt nephropathy. This timely 
intervention is crucial, as when BK virus nephropathy 
is established, treatment becomes more complex and 
immunosuppression reduction is often not sufficient 
to stabilize renal function. Furthermore, the efficacy 
of adjuvant treatment with agents with antiviral activity 
remains to be proven.
A recent study revealed efficacy and safety of IVIG 
as adjuvant treatment of BK virus nephropathy. The case 
presented here may strengthens these outcomes. How-
ever, randomized trials are needed to define the ade-
quate adjunctive therapy for cases of BK virus nephropa-
thy with no response to immunosuppression alone.
Disclosure of potential conflict of interest: None declared.
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